Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$47.2 million.

  • Axsome Therapeutics' Consolidated Net Income rose 2689.24% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 2619.57%. This contributed to the annual value of -$287.2 million for FY2024, which is 2005.45% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Consolidated Net Income of -$47.2 million as of Q3 2025, which was up 2689.24% from -$47.9 million recorded in Q2 2025.
  • Axsome Therapeutics' Consolidated Net Income's 5-year high stood at -$11.2 million during Q1 2023, with a 5-year trough of -$98.6 million in Q4 2023.
  • For the 4-year period, Axsome Therapeutics' Consolidated Net Income averaged around -$57.9 million, with its median value being -$61.2 million (2022).
  • In the last 5 years, Axsome Therapeutics' Consolidated Net Income surged by 7164.41% in 2023 and then tumbled by 50826.66% in 2024.
  • Axsome Therapeutics' Consolidated Net Income (Quarter) stood at -$61.2 million in 2022, then plummeted by 61.06% to -$98.6 million in 2023, then grew by 24.05% to -$74.9 million in 2024, then surged by 36.95% to -$47.2 million in 2025.
  • Its Consolidated Net Income was -$47.2 million in Q3 2025, compared to -$47.9 million in Q2 2025 and -$59.4 million in Q1 2025.